HPK

HighPeak's FY2025 numbers tell a stark story of operational and financial deterioration. Revenue fell 22.7% to $863M and net income collapsed 80.1% to just $19M, driving ROE down to a paltry 1.2% and net margin to 2.2%. The MD&A attributes this to 'decreased revenues associated with lower commodity prices and decreased sales volumes as a result of natural decline and decreased drilling and completion activity' — a dangerous combination for an E&P, since natural decline is structural and lower activity (cutting from two rigs to one in 2026) only accelerates the production roll-off. At $6.98, the stock trades at 49.9x trailing EPS, a valuation that makes no sense for a single-basin oil producer with shrinking output and falling realizations.

The balance sheet is the bigger red flag. Long-term debt grew 22% to $1.13B while the company drew an additional $180M on the Term Loan in August 2025 'providing additional liquidity' and deferred $30M quarterly amortization payments for a year. More alarmingly, the December 2025 Second Term Loan Amendment cut the required asset coverage ratio by 0.25x — covenant relief is rarely a sign of strength, it's a sign management saw they would breach. With $1.2B drawn on the Term Loan against $1.59B of equity and only $162M of cash, the company is one commodity downturn away from real distress. Operating cash flow fell $179M YoY and barely covered $515M of investing outflows, with the gap plugged by debt.